504 related articles for article (PubMed ID: 22128082)
1. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
[TBL] [Abstract][Full Text] [Related]
2. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH;
Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
[TBL] [Abstract][Full Text] [Related]
3. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
[TBL] [Abstract][Full Text] [Related]
4. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
6. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C
Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
[TBL] [Abstract][Full Text] [Related]
8. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
Mok CC; Ho CT; Siu YP; Chan KW; Kwan TH; Lau CS; Wong RW; Au TC
Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
[TBL] [Abstract][Full Text] [Related]
9. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
[TBL] [Abstract][Full Text] [Related]
10. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
Shen K; Yu Y; Tang Z; Liu Z; Li L
Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
[TBL] [Abstract][Full Text] [Related]
11. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
[TBL] [Abstract][Full Text] [Related]
12. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Cauli A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Ann Rheum Dis; 2010 Jan; 69(1):61-4. PubMed ID: 19155235
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
14. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
[TBL] [Abstract][Full Text] [Related]
15. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
[TBL] [Abstract][Full Text] [Related]
16. Treatment of proliferative lupus nephritis: a changing landscape.
Adu D
Kidney Int; 2006 Aug; 70(4):616-8. PubMed ID: 16900218
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone.
Grootscholten C; Dieker JW; McGrath FD; Roos A; Derksen RH; van der Vlag J; Daha MR; Berden JH
Ann Rheum Dis; 2007 May; 66(5):693-6. PubMed ID: 17135217
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.
Illei GG; Austin HA; Crane M; Collins L; Gourley MF; Yarboro CH; Vaughan EM; Kuroiwa T; Danning CL; Steinberg AD; Klippel JH; Balow JE; Boumpas DT
Ann Intern Med; 2001 Aug; 135(4):248-57. PubMed ID: 11511139
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
